Radiopharm Theranostics (RADX) Other Accumulated Expenses (2024)
Radiopharm Theranostics' Other Accumulated Expenses was $654,427 in fiscal Q4 2026 (quarter ended Jun 30, 2026), up 3.6% from $631,898 a year earlier.
Powered by 
Analysis
Radiopharm Theranostics (RADX) Other Accumulated Expenses (2024) Analysis & Trends
At the end of FY2026 (ended Jun 30, 2026), Other Accumulated Expenses at Radiopharm Theranostics came in at $626,572, down 0.8% from FY2025.
- In earlier fiscal years, Other Accumulated Expenses was $631,898 in FY2025 (+286.2%) and $163,637 in FY2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,261.99 Bn | 1,235.61 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 678.93 Bn | 598.79 Bn | 17.30 Bn |
| 3 | AbbVie | 518.29 Bn | 486.30 Bn | 13.12 Bn |
| 4 | Merck | 365.98 Bn | 328.92 Bn | 13.19 Bn |
| 5 | Novartis Ag | 316.85 Bn | 290.09 Bn | - |
| 6 | Astrazeneca | 293.40 Bn | 267.29 Bn | 13.26 Bn |
| 7 | Amgen | 251.78 Bn | 203.43 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 210.61 Bn | 185.71 Bn | 6.73 Bn |
| 9 | Pfizer | 166.87 Bn | 114.23 Bn | 12.56 Bn |
| 10 | Radiopharm Theranostics | 2.70 Bn | 2.62 Bn | - |
API Access
Radiopharm Theranostics Other Accumulated Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=RADX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "other-accumulated-expenses", "ticker": "RADX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=RADX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();